Financhill
Buy
52

INVA Quote, Financials, Valuation and Earnings

Last price:
$19.43
Seasonality move :
0.75%
Day range:
$19.37 - $19.87
52-week range:
$16.19 - $22.00
Dividend yield:
0%
P/E ratio:
98.63x
P/S ratio:
3.88x
P/B ratio:
1.88x
Volume:
903.9K
Avg. volume:
1M
1-year change:
17.58%
Market cap:
$1.2B
Revenue:
$358.7M
EPS (TTM):
-$1.01

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
INVA
Innoviva
$87.1M $0.43 -12.81% -46.05% $55.00
ATNM
Actinium Pharmaceuticals
-- -$0.35 -100% -7.24% $5.00
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
INVA
Innoviva
$19.40 $55.00 $1.2B 98.63x $0.00 0% 3.88x
ATNM
Actinium Pharmaceuticals
$1.43 $5.00 $44.6M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.63 $0.85 $3.6M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.39 -- $22.3M -- $0.00 0% --
OGEN
Oragenics
$1.44 $1.00 $1M -- $0.00 0% 0.46x
TOVX
Theriva Biologics
$0.45 $7.00 $3.7M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
INVA
Innoviva
40.97% 0.417 39.44% 2.24x
ATNM
Actinium Pharmaceuticals
-- -3.037 -- 9.03x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
NNVC
Nanoviricides
-- -0.318 -- --
OGEN
Oragenics
-- 0.068 -- --
TOVX
Theriva Biologics
-- -3.388 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
INVA
Innoviva
$79.8M $41.4M -5.32% -8.85% -38.22% $48.6M
ATNM
Actinium Pharmaceuticals
-- -$16.6M -95.08% -95.08% -12769.14% -$7.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Innoviva vs. Competitors

  • Which has Higher Returns INVA or ATNM?

    Actinium Pharmaceuticals has a net margin of -52.56% compared to Innoviva's net margin of -11511.11%. Innoviva's return on equity of -8.85% beat Actinium Pharmaceuticals's return on equity of -95.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    INVA
    Innoviva
    90.02% -$0.74 $1.1B
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
  • What do Analysts Say About INVA or ATNM?

    Innoviva has a consensus price target of $55.00, signalling upside risk potential of 183.51%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 249.65%. Given that Actinium Pharmaceuticals has higher upside potential than Innoviva, analysts believe Actinium Pharmaceuticals is more attractive than Innoviva.

    Company Buy Ratings Hold Ratings Sell Ratings
    INVA
    Innoviva
    0 0 0
    ATNM
    Actinium Pharmaceuticals
    2 1 0
  • Is INVA or ATNM More Risky?

    Innoviva has a beta of 0.372, which suggesting that the stock is 62.761% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.325, suggesting its less volatile than the S&P 500 by 132.486%.

  • Which is a Better Dividend Stock INVA or ATNM?

    Innoviva has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INVA or ATNM?

    Innoviva quarterly revenues are $88.6M, which are larger than Actinium Pharmaceuticals quarterly revenues of $81K. Innoviva's net income of -$46.6M is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Innoviva's price-to-earnings ratio is 98.63x while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva is 3.88x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INVA
    Innoviva
    3.88x 98.63x $88.6M -$46.6M
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
  • Which has Higher Returns INVA or NBY?

    NovaBay Pharmaceuticals has a net margin of -52.56% compared to Innoviva's net margin of -49.65%. Innoviva's return on equity of -8.85% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    INVA
    Innoviva
    90.02% -$0.74 $1.1B
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About INVA or NBY?

    Innoviva has a consensus price target of $55.00, signalling upside risk potential of 183.51%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 35.98%. Given that Innoviva has higher upside potential than NovaBay Pharmaceuticals, analysts believe Innoviva is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    INVA
    Innoviva
    0 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is INVA or NBY More Risky?

    Innoviva has a beta of 0.372, which suggesting that the stock is 62.761% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock INVA or NBY?

    Innoviva has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INVA or NBY?

    Innoviva quarterly revenues are $88.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Innoviva's net income of -$46.6M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Innoviva's price-to-earnings ratio is 98.63x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva is 3.88x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INVA
    Innoviva
    3.88x 98.63x $88.6M -$46.6M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns INVA or NNVC?

    Nanoviricides has a net margin of -52.56% compared to Innoviva's net margin of --. Innoviva's return on equity of -8.85% beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    INVA
    Innoviva
    90.02% -$0.74 $1.1B
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About INVA or NNVC?

    Innoviva has a consensus price target of $55.00, signalling upside risk potential of 183.51%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 367.63%. Given that Nanoviricides has higher upside potential than Innoviva, analysts believe Nanoviricides is more attractive than Innoviva.

    Company Buy Ratings Hold Ratings Sell Ratings
    INVA
    Innoviva
    0 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is INVA or NNVC More Risky?

    Innoviva has a beta of 0.372, which suggesting that the stock is 62.761% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.

  • Which is a Better Dividend Stock INVA or NNVC?

    Innoviva has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INVA or NNVC?

    Innoviva quarterly revenues are $88.6M, which are larger than Nanoviricides quarterly revenues of --. Innoviva's net income of -$46.6M is lower than Nanoviricides's net income of -$2.2M. Notably, Innoviva's price-to-earnings ratio is 98.63x while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva is 3.88x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INVA
    Innoviva
    3.88x 98.63x $88.6M -$46.6M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns INVA or OGEN?

    Oragenics has a net margin of -52.56% compared to Innoviva's net margin of --. Innoviva's return on equity of -8.85% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    INVA
    Innoviva
    90.02% -$0.74 $1.1B
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About INVA or OGEN?

    Innoviva has a consensus price target of $55.00, signalling upside risk potential of 183.51%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1983.54%. Given that Oragenics has higher upside potential than Innoviva, analysts believe Oragenics is more attractive than Innoviva.

    Company Buy Ratings Hold Ratings Sell Ratings
    INVA
    Innoviva
    0 0 0
    OGEN
    Oragenics
    0 1 0
  • Is INVA or OGEN More Risky?

    Innoviva has a beta of 0.372, which suggesting that the stock is 62.761% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock INVA or OGEN?

    Innoviva has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INVA or OGEN?

    Innoviva quarterly revenues are $88.6M, which are larger than Oragenics quarterly revenues of --. Innoviva's net income of -$46.6M is lower than Oragenics's net income of -$2.2M. Notably, Innoviva's price-to-earnings ratio is 98.63x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva is 3.88x versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INVA
    Innoviva
    3.88x 98.63x $88.6M -$46.6M
    OGEN
    Oragenics
    0.46x -- -- -$2.2M
  • Which has Higher Returns INVA or TOVX?

    Theriva Biologics has a net margin of -52.56% compared to Innoviva's net margin of --. Innoviva's return on equity of -8.85% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    INVA
    Innoviva
    90.02% -$0.74 $1.1B
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About INVA or TOVX?

    Innoviva has a consensus price target of $55.00, signalling upside risk potential of 183.51%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1455.56%. Given that Theriva Biologics has higher upside potential than Innoviva, analysts believe Theriva Biologics is more attractive than Innoviva.

    Company Buy Ratings Hold Ratings Sell Ratings
    INVA
    Innoviva
    0 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is INVA or TOVX More Risky?

    Innoviva has a beta of 0.372, which suggesting that the stock is 62.761% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock INVA or TOVX?

    Innoviva has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INVA or TOVX?

    Innoviva quarterly revenues are $88.6M, which are larger than Theriva Biologics quarterly revenues of --. Innoviva's net income of -$46.6M is lower than Theriva Biologics's net income of -$4.3M. Notably, Innoviva's price-to-earnings ratio is 98.63x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva is 3.88x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INVA
    Innoviva
    3.88x 98.63x $88.6M -$46.6M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Why Is Goldman Sachs Stock Up So Much?
Why Is Goldman Sachs Stock Up So Much?

Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…

Stock Ideas

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Sell
18
CNC alert for Jul 3

Centene [CNC] is down 40.18% over the past day.

Sell
12
MOH alert for Jul 3

Molina Healthcare [MOH] is down 22.06% over the past day.

Buy
67
GBX alert for Jul 3

Greenbrier Companies [GBX] is up 21.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock